Healthcare Industry News: metabolic disease
News Release - April 22, 2009
Metabolex Announces Election of Kurt von Emster to Board of DirectorsHAYWARD, Calif., April 22 -- (Healthcare Sales & Marketing Network) -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new therapeutics for the treatment of diabetes and related metabolic disorders, announced that Kurt von Emster has been elected to its Board of Directors.
Mr. von Emster currently serves as a Managing Director of venBio. From November 2000 to March 2009, Mr. von Emster was Managing Director of MPM BioEquities and a Portfolio Manager for the MPM BioEquities Fund. From July 1989 to November 2000, Mr. von Emster was with the Franklin Templeton Group, most recently as a Vice President and Portfolio Manager. Mr. von Emster is currently a member of the board of directors at Somaxon Pharmaceuticals, Inc., and Facet Biotech, both public biotechnology companies. Mr. von Emster is a Chartered Financial Analyst (CFA), a member of the Association for Investment Management and Research and of the Security Analysts of San Francisco. Mr. von Emster received his B.S. degree from the University of California at Santa Barbara.
"Mr. von Emster brings to the Board the perspective of a seasoned private and public company investor," said Harold Van Wart, Ph.D., president and chief executive officer of Metabolex. "We look forward to his input and expertise as the company continues to build upon its recent clinical successes." Mr. von Emster's appointment follows the resignation of Rob Chess from the Board of Directors. Dr. Van Wart added, "I would like to thank Rob for his many valuable contributions to Metabolex during his Board tenure."
Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawn on its deep understanding of diabetes to create a large database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company has four clinical-stage compounds: MBX-102/JNJ 39659100, which has completed three Phase 2 trials; MBX-2044, which has completed a Phase 2a trial; MBX-8025, which has completed a Phase 2 trial in patients with dyslipidemia; and MBX-2982, which has completed a Phase 1 trial. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102/JNJ 39659100. For additional information about Metabolex and its development pipeline, visit www.metabolex.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.